Loading...
The CYP2C19*2 allele is a common variant associated with high platelet reactivity and increased rates of adverse events after percutaneous coronary intervention (PCI) in patients taking clopidogrel. So far, the inability to perform bedside genetic testing has prevented prospective patient assessment for this allele. Now, a simple point-of-care genetic test (validated by conventional genetic testing) has emerged that identifies CYP2C19*2 carrier status within 60 minutes of activation. Results classify individuals as homozygous for the wild-type allele (*1/*1), heterozygous (*1/*2), or homozygous for the *2 allele (*2/*2).
In a randomized, proof-of-concept study sponsored by the device manufacturer, 200 patients undergoing PCI for acute corona…